Rname Pharmaceutical Technology

Rname Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapies for autoimmune and inflammatory diseases. The company's primary focus is on the development of highly selective kinase inhibitors, particularly targeting the Janus kinase (JAK) and Tyrosine kinase 2 (TYK2) pathways. Their lead candidate, RN-439, is a potent and selective TYK2 inhibitor currently undergoing clinical evaluation for conditions such as psoriasis and atopic dermatitis. Rname aims to provide safer and more effective treatment options for patients with chronic immune-mediated disorders by leveraging its expertise in medicinal chemistry and structure-based drug design.